Prevention of hepatocellular carcinoma: Progress and challenges

Minerva Gastroenterologica e Dietologica

Volumn 58, Issue 1, 2012, Pages 49-64

  Shire, A M ^a   Roberts, L R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Carcinoma, hepatocellular; Hepatitis B; Hepatitis C; Virus diseases

Indexed keywords

ACETALDEHYDE; AFLATOXIN; ALPHA INTERFERON; CYTOCHROME P450 2E1; DNA VACCINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; VIRUS DNA; VIRUS RNA;

ALCOHOL CONSUMPTION; ALCOHOLIC BEVERAGE; ALCOHOLISM; BODY MASS; CANCER PREVENTION; CANCER RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EATING HABIT; ENVIRONMENTAL EXPOSURE; EXPOSURE; GENOTYPE; HEPATITIS B; HEPATITIS C; HUMAN; INCIDENCE; LIFESTYLE MODIFICATION; LIVER CELL CARCINOMA; NONALCOHOLIC FATTY LIVER; OBESITY; PHYSICAL ACTIVITY; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SEROCONVERSION; SMOKING; TREATMENT DURATION; VACCINATION; VIRAL CLEARANCE; VIRUS CARRIER; VIRUS LIKE AGENT;

AFLATOXINS; ALCOHOL DRINKING; CARCINOMA, HEPATOCELLULAR; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DIET; EARLY DIAGNOSIS; EVIDENCE-BASED MEDICINE; FATTY LIVER; HEPATITIS B; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER NEOPLASMS; MINNESOTA; POISONS; PREVALENCE; RISK FACTORS; SMOKING; WORLD HEALTH;

EID: 84860308049     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular Carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27:1485-91.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
3. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-76. (Pubitemid 46890874)
4. Krugman S, Overby LR, Mushahwar IK, Ling CM, Frosner GG, Deinhardt F. Viral hepatitis, type B. Studies on natural history and prevention re-examined. N Engl J Med 1979;300:101-6. (Pubitemid 9116289)
5. World Health Organization HBvWW. Hepatitis B. Fact Sheet 204 2008.
6. World Health Organization. WHO expanded programme on immunisation. Global Advisory Group. Weekly Epidemiol Rec 1992;3:11-6.
7. World Health Organization. Hepatitis C. Fact Sheet No. 164 June 2011. 2011.
8. Chang MH. Cancer prevention by vaccination against hepatitis B. Recent Results Cancer Res 2009;181:85-94.
9. Chan CY, Lee SD, Lo KJ. Legend of hepatitis B vaccination: the Taiwan experience. J Gastroenterol Hepatol 2004;19:121-6.
10. Viviani S, Jack A, Hall AJ, Maine N, Mendy M, Montesano R et al. Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age. Vaccine 1999;17:2946-50. (Pubitemid 29366973)
11. Whittle HC, Maine N, Pilkington J, Mendy M, Fortuin M, Bunn J et al. Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages. Lancet 1995;345:1089-92.
12. Ng KP, Saw TL, Baki A, Rozainah K, Pang KW, Ramanathan M. Impact of the Expanded Program of Immunization against hepatitis B infection in school children in Malaysia. Med Microbiol Immunol 2005;194:163-8. (Pubitemid 41202533)
13. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336:1855-9.
14. Tajiri H, Tanaka H, Brooks S, Takano T. Reduction of hepatocellular carcinoma in childhood after introduction of selective vaccination against hepatitis B virus for infants born to HBV carrier mothers. Cancer Causes Control 2011;22:523-7.
15. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. Jama 2006;295:65-73. (Pubitemid 43042691)
16. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-86. (Pubitemid 43374518)
17. Lin SM, Yu ML, Lee CM, Chien RN, Sheen IS, Chu CM et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007;46:45-52.
18. Ikeda K, Kobayashi M, Saitoh S, Someya T, Hosaka T, Akuta N et al. Significance of hepatitis B virus DNA clearance and early prediction of hepatocellular carcinogenesis in patients with cirrhosis undergoing interferon therapy: long-term follow up of a pilot study. J Gastroenterol Hepatol 2005;20:95-102. (Pubitemid 40143640)
19. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-31.
20. Di Marco V, Marzano A, Lampertico P, Andreone P, Santantonio T, Almasio PL et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004;40:883-91. (Pubitemid 39288121)
21. Eun JR, Lee HJ, Kim TN, Lee KS. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease. J Hepatol 2010;53:118-25.
22. Matsumoto A, Tanaka E, Rokuhara A, Kiyosawa K, Kumada H, Omata M et al. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients. Hepatol Res 2005;32:173-84. (Pubitemid 41078655)
23. Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000;355:887-91. (Pubitemid 30137669)
24. Wong V, Caronia S, Wight D, Palmer CR, Petrik J, Britton P et al. Importance of age in chronic hepatitis C virus infection. J Viral Hepat 1997;4:255-64. (Pubitemid 127733432)
25. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-32. (Pubitemid 27129209)
26. Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbmzzese JL et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002;36:1206-13. (Pubitemid 35253437)
27. Tsochatzis E, Papatheodoridis GV, Manolakopoulos S, Tiniakos DG, Manesis EK, Archimandritis AJ. Smoking is associated with steatosis and severe fibrosis in chronic hepatitis C but not B. Scand J Gastroenterol 2009;44:752-9.
28. Ohki T, Tateishi R, Sato T, Masuzaki R, Imamura J, Goto T et al. Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. Clin Gastroenterol Hepatol 2008;6:459-64. (Pubitemid 351443115)
29. Houghton M. Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses. Immunol Rev 2011;239:99-108.
30. Stoll-Keller F, Barth H, Fafi-Kremer S, Zeisel MB, Baumert TF. Development of hepatitis C virus vaccines: challenges and progress. Expert Rev Vaccines 2009;8:333-45.
31. Yu CI, Chiang BL. A new insight into hepatitis C vaccine development. J Biomed Biotechnol 2011;2010:548280.
32. Meunier JC, Gottwein JM, Houghton M, Russell RS, Emerson SU, Bukh J et al. Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus. J Infect Dis 2011;204:1186-90.
33. Garrone P, Fluckiger AC, Mangeot PE, Gauthier E, Dupeyrot-Lacas P, Mancip J et al. A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci Transl Med 2011;3-94ra71.
34. Drane D, Maraskovsky E, Gibson R, Mitchell S, Barnden M, Moskwa A et al. Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRLX vaccine: a phase I study in healthy volunteers. Hum Vaccin 2009;5:151-7.
35. Firbas C, Jilma B, Tauber E, Buerger V, Jelovcan S, Lingnau K et al. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine 2006;24:4343-53•
36. Klade CS, Wedemeyer H, Berg T, Hinrichsen H, Cholewinska G, Zeuzem S et al. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology 2008;134:1385-95.
37. Kanduc D, Tessitore L, Lucchese G, Kusalik A, Farber E, Marincola FM. Sequence uniqueness and sequence variability as modulating factors of human anti-HCV humoral immune response. Cancer Immunol Immunother 2008;57:1215-23.
38. Folgori A, Capone S, Ruggeri L, Meola A, Sporeno E, Ercole BB et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med 2006;12:190-7. (Pubitemid 43214745)
39. Alvarez-Lajonchere L, Shoukry NH, Gra B, Amador-Canizares Y, Helle F, Bedard N et al. Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial. J Viral Hepat 2009;16:156-67.
40. Shiratori Y, Ito Y, Yokosuka O, Imazeki F, Nakata R, Tanaka N et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005;142:105-14.
41. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999;131:174-81. (Pubitemid 29364999)
42. Poordad F, McCone J, Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206.
43. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16.
44. McKillop IH, Schrum LW. Alcohol and liver cancer. Alcohol 2005;35:195-203. (Pubitemid 41079923)
45. McKillop IH, Schrum LW. Role of alcohol in liver carcinogenesis. Semin Liver Dis 2009;29:222-32.
46. Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002;155:323-31. (Pubitemid 34132050)
47. Tagger A, Donato F, Ribero ML, Chiesa R, Portera G, Gelatti U et al. Case-control study on hepatitis C virus (HCV) as a risk factor for hepatocellular carcinoma: the role of HCV genotypes and the synergism with hepatitis B virus and alcohol. Brescia HCC Study. Int J Cancer 1999;81:695-9. (Pubitemid 29214375)
48. World Health Organization. Alcohol. Fact Sheet, February 2011. 2011.
49. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-8. (Pubitemid 10057164)
50. Schaffner F, Thaler H. Nonalcoholic fatty liver disease. Prog Liver Dis 1986;8:283-98.
51. Hashimoto E, Tokushige K. Hepatocellular carcinoma in non-alcoholic steatohepatitis: Growing evidence of an epidemic? Hepatol Res 2012;42:1-14.
52. Yasui K, Hashimoto E, Komorizono Y, Koike K, Arii S, Imai Y et al. Characteristics of patients with non-alcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011;9:428-33; quiz e50.
53. Ertle J, Dechene A, Sowa JP, Penndorf V, Herzer K, Kaiser G et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 2011;128:2436-43.
54. Ohata K, Hamasaki K, Toriyama K, Matsumoto K, Saeki A, Yanagi K et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 2003;97:3036-43. (Pubitemid 36676258)
55. Grattagliano I, Portincasa P, Palmieri VO, Palasciano G. Managing nonalcoholic fatty liver disease: recommendations for family physicians. Can Fam Physician 2007;53:857-63. (Pubitemid 47164278)
56. Bulatao-Jayme J, Almero EM, Castro MC, Jardeleza MT, Salamat LA. A case-control dietary study of primary liver cancer risk from aflatoxin exposure. Int J Epidemiol 1982;11:112-9. (Pubitemid 12071053)
57. Peers FG, Linsell CA. Dietary aflatoxins and human primary liver cancer. Ann Nutr Aliment 1977;31:1005-17.
58. Van Rensburg SJ, Cook-Mozaffari P, Van Schalkwyk DJ, Van der Watt JJ, Vincent TJ, Purchase IF. Hepatocellular carcinoma and dietary aflatoxin in Mozambique and Transkei. Br J Cancer 1985;51:713-26.
59. Qian GS, Ross RK, Yu MC, Yuan JM, Gao YT, Henderson BE et al. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prev 1994;3:3-10. (Pubitemid 24172514)
60. Chen CJ, Wang LY, Lu SN, Wu MH, You SL, Zhang YJ et al. Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma. Hepatology 1996;24:38-42.
61. Wild CP, Rasheed FN, Jawla MF, Hall AJ, Jansen LA, Montesano R. In-utero exposure to aflatoxin in west Africa. Lancet 1991;337:1602.
62. Wild CP, Yin F, Turner PC, Chemin I, Chapot B, Mendy M et al. Environmental and genetic determinants of aflatoxin-albumin adducts in the Gambia. Int J Cancer 2000;86:1-7. (Pubitemid 30133979)
63. Aguilar F, Hussain SP, Cerutti P. Aflatoxin B1 induces the transversion of G→T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc Natl Acad Sci U S A 1993;90:8586-90. (Pubitemid 23277714)
64. Deng ZL, Ma Y. Aflatoxin sufferer and p53 gene mutation in hepatocellular carcinoma. World J Gastroenterol 1998;4:28-29. (Pubitemid 128620100)
65. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991;350:429-31. (Pubitemid 21912246)
66. Coursaget P, Depril N, Chabaud M, Nandi R, Mayelo V, LeCann P et al. High prevalence of mutations at codon 249 of the p53 gene in hepatocellular carcinomas from Senegal. Br J Cancer 1993;67:1395-7. (Pubitemid 23172885)
67. Ross RK, Yuan JM, Yu MC, Wogan GN, Qian GS, Tu JT et al. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 1992;339:943-6.
68. Turner PC, Sylla A, Gong YY, Diallo MS, Sutcliffe AE, Hall AJ et al. Reduction in exposure to carcinogenic aflatoxins by postharvest intervention measures in west Africa: a community-based intervention study. Lancet 2005;365:1950-6. (Pubitemid 40797504)
69. Mizoue T, Tokui N, Nishisaka K, Nishisaka S, Ogimoto I, Ikeda M et al. Prospective study on the relation of cigarette smoking with cancer of the liver and stomach in an endemic region. Int J Epidemiol 2000;29:232-7. (Pubitemid 30209812)
70. Koh WP, Robien K, Wang R, Govindarajan S, Yuan JM, Yu MC. Smoking as an independent risk factor for hepatocellular carcinoma: the Singapore Chinese Health Study. Br J Cancer 2011;105:1430-5.
71. Dubois G, Braillon A. Hepatocellular carcinoma: again, tobacco is the first enemy. Int J Epidemiol 2010;39:1399.
72. Zhu K, Moriarty C, Caplan LS, Levine RS. Cigarette smoking and primary liver cancer: a population-based case-control study in US men. Cancer Causes Control 2007;18:315-21. (Pubitemid 46356213)
73. Jee SH, Ohrr H, Sull JW, Samet JM. Cigarette smoking, alcohol drinking, hepatitis B, and risk for hepatocellular carcinoma in Korea. J Natl Cancer Inst 2004;96:1851-6. (Pubitemid 40081322)
74. Ogimoto I, Shibata A, Kurozawa Y, Nose T, Yoshimura T, Suzuki H et al. Risk of death due to hepatocellular carcinoma among smokers and ex-smokers. Univariate analysis of JACC study data. Kurume Med J 2004;51:71-81. (Pubitemid 38856179)
75. Gotay CC. Behavior and cancer prevention. J Clin Oncol 2005;23:301-10. (Pubitemid 46206881)
76. WHO. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000;894.i-xii, 1-253.
77. World Health Organization. Obesity and overweight. Fact Sheet No. 311 March 2011. 2011.
78. Larsson SC, Wolk A. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer 2007;97:1005-8. (Pubitemid 47519294)
79. Polesel J, Zucchetto A, Montella M, Dal Maso L, Crispo A, La Vecchia C et al. The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. Ann Oncol 2009;20:353-7.
80. Trichopoulos D, Bamia C, Lagiou P, Fedirko V, Trepo E, Jenab M et al. Hepatocellular carcinoma risk factors and disease burden in a european cohort: a nested case-control study. J Natl Cancer Inst 2011.
81. Fan JG, Farrell GC. Prevention of hepatocellular carcinoma in nonviral-related liver diseases. J Gastroenterol Hepatol 2009;24:712-9.
82. World Health Organization. Diabetes. Fact Sheet No. 312 August 2011. 2011.
83. Wang P, Kang D, Cao W, Wang Y, Liu Z. Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. Diabetes Metab Res Rev 2011.
84. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006;4:369-80. (Pubitemid 43343895)